These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 19130320)
21. Predictive value of multiple metabolic and heterogeneity parameters of Shi A; Wang J; Wang Y; Guo G; Fan C; Liu J Ann Nucl Med; 2022 Apr; 36(4):393-400. PubMed ID: 35084711 [TBL] [Abstract][Full Text] [Related]
22. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Mori M; Endo K J Nucl Med; 2009 Nov; 50(11):1770-6. PubMed ID: 19837768 [TBL] [Abstract][Full Text] [Related]
23. Predicting pleural invasion using HRCT and 18F-FDG PET/CT in lung adenocarcinoma with pleural contact. Tanaka T; Shinya T; Sato S; Mitsuhashi T; Ichimura K; Soh J; Toyooka S; Kaji M; Miyoshi S; Kanazawa S Ann Nucl Med; 2015 Nov; 29(9):757-65. PubMed ID: 26142739 [TBL] [Abstract][Full Text] [Related]
24. Predictive value of intratumor metabolic and heterogeneity parameters on [ Ni M; Wang S; Liu X; Shi Q; Zhu X; Zhang Y; Xie Q; Lv W Jpn J Radiol; 2023 Feb; 41(2):209-218. PubMed ID: 36219311 [TBL] [Abstract][Full Text] [Related]
25. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients. Lee SM; Bae SK; Jung SJ; Kim CK Clin Nucl Med; 2015 Dec; 40(12):950-8. PubMed ID: 26359571 [TBL] [Abstract][Full Text] [Related]
26. Imaging characteristics of stage I non-small cell lung cancer on CT and FDG-PET: relationship with epidermal growth factor receptor protein expression status and survival. Lee Y; Lee HJ; Kim YT; Kang CH; Goo JM; Park CM; Paeng JC; Chung DH; Jeon YK Korean J Radiol; 2013; 14(2):375-83. PubMed ID: 23483676 [TBL] [Abstract][Full Text] [Related]
27. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs. Yoshida T; Tanaka H; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Iwata H; Hida T; Yatabe Y Lung Cancer; 2016 Oct; 100():14-19. PubMed ID: 27597275 [TBL] [Abstract][Full Text] [Related]
28. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. Choi H; Paeng JC; Kim DW; Lee JK; Park CM; Kang KW; Chung JK; Lee DS Lung Cancer; 2013 Mar; 79(3):242-7. PubMed ID: 23261227 [TBL] [Abstract][Full Text] [Related]
29. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma. Yanarateş A; Yazici B Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695 [TBL] [Abstract][Full Text] [Related]
30. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis. Chen L; Zhou Y; Tang X; Yang C; Tian Y; Xie R; Chen T; Yang J; Jing M; Chen F; Wang C; Sun H; Huang Y Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083 [TBL] [Abstract][Full Text] [Related]
31. EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: investigation of significantly related factors on CT, FDG-PET, and histopathology. Park EA; Lee HJ; Kim YT; Kang CH; Kang KW; Jeon YK; Goo JM; Lee CH; Park CM Lung Cancer; 2009 May; 64(2):179-86. PubMed ID: 18819724 [TBL] [Abstract][Full Text] [Related]
32. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369 [TBL] [Abstract][Full Text] [Related]
33. Prognostic value of combining clinical factors, Lue KH; Chen YH; Chu SC; Lin CB; Wang TF; Liu SH Ann Nucl Med; 2024 Aug; 38(8):647-658. PubMed ID: 38704786 [TBL] [Abstract][Full Text] [Related]
34. Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Jeong HJ; Min JJ; Park JM; Chung JK; Kim BT; Jeong JM; Lee DS; Lee MC; Han SK; Shim YS Nucl Med Commun; 2002 Sep; 23(9):865-70. PubMed ID: 12195091 [TBL] [Abstract][Full Text] [Related]
35. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396 [TBL] [Abstract][Full Text] [Related]
36. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas. Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687 [TBL] [Abstract][Full Text] [Related]
37. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Kidd EA; Siegel BA; Dehdashti F; Grigsby PW Cancer; 2007 Oct; 110(8):1738-44. PubMed ID: 17786947 [TBL] [Abstract][Full Text] [Related]
38. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. Downey RJ; Akhurst T; Gonen M; Vincent A; Bains MS; Larson S; Rusch V J Clin Oncol; 2004 Aug; 22(16):3255-60. PubMed ID: 15310769 [TBL] [Abstract][Full Text] [Related]
39. The diagnostic and predictive efficacy of Guo Y; Zhu H; Yao Z; Liu F; Yang D Eur J Radiol; 2021 Aug; 141():109792. PubMed ID: 34062472 [TBL] [Abstract][Full Text] [Related]
40. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions. Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]